Utilizing Population Health Outcomes Data to Increase Adult Pneumococcal Immunization Rates

Pfizer Final Report
Submitted by:
University of Cincinnati
Center for Continuous Professional Development
Tiffiny Diers, MD
Principal Investigator
August 10, 2015
In collaboration with
Direct One Communications
Confluent Healthcare Solutions
Humedica

AMGA



Aim and Goals


The aim of this PI-CME activity was to improve clinical outcomes and address barriers related to pneumococcal vaccination.


❖ Goals:

- ❖ Increase the percent of eligible patients, ≤65 who have received a pneumococcal vaccination within the time period of the project.
- ❖ Increase the percentage of people, ages 19 to 64, who have chronic illness or at high risk for infection, including chronic cardiac, pulmonary, liver disease, or diabetes.



Outcomes







Impact on Number of Patients Vaccinated

Patient group	Number physicians	Finished CME?	Number of eligible patients	Number vaccinated at baseline assessment	Number vaccinated at final assessment	Change from baseline in number of patients vaccinated	
Elderly	103	Yes	35,384	20,853	26,345	+ 5,492	(+ 26.3%)
	217	No	70,098	43,362	52,630	+ 9,268	(+ 21.4%)
Total	320	-	105,482	64,215	78,975	+ 14,760	(+ 23.0%)
High-risk	103	Yes	61,326	8,786	12,661	+ 3,875	(+ 44.1%)
	217	No	101,349	14,576	19,645	+ 5,069	(+ 34.8%)
Total	320	-	162,675	23,362	32,306	+ 8,944	(+ 38.3%)



Conclusions

- Nearly a third (103/316) of the primary care physicians who participated in this program completed the PI CME educational activities offered and received 20 AMA PRA CreditsTM.
- The program was successful in driving up pneumococcal vaccination rates: a total of 14,760 elderly patients and 8,944 patients at high risk of pneumococcal infection in just three medical groups were vaccinated post baseline over its two-year course.
- Access to the Clinical Performance Dashboard alone improved pneumococcal vaccination rates by 20% to 42%.
- In addition, finishing the CME program worked even better, improving pneumococcal vaccination rates by 22% to 53%, especially in vaccinating younger patients at high risk.
- The program achieved both Moore's Level 5 (Performance) and Level 6 (Patient Health Status).

